AstraZeneca is responding to the COVID-19 (novel coronavirus) outbreak, consistent with our values to follow the science, put patients first and do the right thing. Our priorities are to ensure the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities.
Our medicines supply chain is robust, and we continue to monitor the situation closely. Our stringent quality management system ensures the safety, quality and efficacy of all our medicines at all times.
As a science-led biopharmaceutical company, our clinical research is crucial to the development of innovative new medicines, and we have taken appropriate measures to ensure continuity and mitigate any impact to our research and development programmes.
To help protect the health and wellbeing of our 70,000 employees around the world and the communities in which we operate, we have implemented temporary measures to help reduce the risk of infection. These include leveraging digital technology to support working-from-home, as well as restricting business travel, off-site meetings and external visitors to AstraZeneca sites. Our guidance is aligned with local government authorities.
AstraZeneca is engaging with international health authorities and governments in response to the outbreak. We have provided our science and technology expertise to authorities including the World Health Organization (WHO) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Through our scientific expertise in infectious disease and proprietary antibody discovery technology, we have rapidly mobilised our research efforts to discovering novel coronavirus-neutralising antibodies as a treatment to prevent COVID-19 disease. Our teams are now focused on identifying monoclonal antibodies to progress into clinical trial evaluation. We look forward to providing more updates on our research soon.